Ascendia

  MARKET NEWS

Sharp Services Invests $100 Million in US & European Facilities to Increase Capacity & Service Offerings
Serán BioScience Expands Commercial Manufacturing With New Campus in Bend, Oregon
Orion & Abzena Announce Exclusive Commercial License for Abzena’s Antibody
Aenova Expands Sterile Fill & Finish Manufacturing Capacity at its Latina Site
Kindeva Announces the Appointment of David Stevens as President
Vertero Unveils New Strategic Direction Focused on Breaking Barriers in Neurodegenerative Diseases
Simcha Therapeutics Presents Preclinical Data Demonstrating Potential for Decoy-Resistant IL-18 to Enhance Efficacy of Bi-specific T-cell Engagers
Evonik Launches EUDRACAP Colon Functional Capsules in GMP Quality at CPHI Frankfurt
Roquette Returns to SupplySide Global With New, Unified Vision for Health & Nutrition
Hovione Completes Initial $100M Investment Cycle to Expand US Operations at New Jersey Manufacturing Campus

  EXPERT CONTENT & RESOURCES

Insights From KPMG: Life Sciences CEOs Double Down on AI & Workforce Readiness

Insights From KPMG: Life Sciences CEOs Double Down on AI & Workforce Readiness

Life sciences CEOs are making decisive moves to secure long-term growth, and the message is clear: standing still is not an option. Findings from the KPMG 2025 CEO Outlook survey show leaders are strategically investing in AI, talent, and operational agility – choosing to accelerate rather than retreat.

How Can a Stage-Based Program to Determine HME Applicability Benefit Your API?

How Can a Stage-Based Program to Determine HME Applicability Benefit Your API?

Low bioavailability due to poor API solubility is one of the major challenges to be overcome when developing oral dosage form drug products. An effective way of addressing this problem is to transform low solubility APIs into amorphous solid dispersions (ASDs) and can often be achieved via hot melt extrusion (HME).

Nitrosamine Risk Assessment and Mitigation in Pharmaceutical Products

Nitrosamine Risk Assessment and Mitigation in Pharmaceutical Products

This paper explores practical approaches for identifying and mitigating nitrosamine risks in drug products, integrating emerging tools such as predictive machine learning, advanced nitrite testing methodologies, and strategic excipient sourcing.

  FEATURED EDITORIAL

  COMPANY PROFILE

nanoComposix, LLC (A Fortis Life Sciences company) headquartered in San Diego, CA provides precisely engineered and highly characterized nanomaterials to a global customer base. nanoComposix is an ISO 13485:2016 certified, FDA-registered developer and contract manufacturer. Click here for more.

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules

ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules

In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products.

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..

  WHITEPAPERS & WEBINARS

WHITEPAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers

WHITEPAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers

 

The biopharmaceutical classification system classifies drugs according to their permeability and solubility. Drugs with poor solubility and/or permeability are class II or IV type drugs, and these require special formulation technologies for solubility enhancement. In the past 25 …

WHITEPAPER - Drug Delivery – Recent Trends, Enabling Technologies, In-Vitro-In-Vivo Predictions & Personalized Medicine

WHITEPAPER - Drug Delivery – Recent Trends, Enabling Technologies, In-Vitro-In-Vivo Predictions & Personalized Medicine

By: Dr. Jens Morgenthaler, General Manager and Dr. Matthias Rischer, Head of Innovation, Losan Pharma GmbH

 Introduction

The successful formulation of small molecules is still one of the important challenges of today, especially if these drugs belong to the BioClassificationSystem …

WHITEPAPER - 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing

WHITEPAPER - 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing

SGS, the world’s leading testing, inspection and certification company, recently announced the release of a new white paper, 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing.

Targeted at researchers, toxicologists and formulation scientists in the clinical and dermatological …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 29 – Formulation Development
November 5 – Drug Delivery